Revvity, Inc. (RVTY) EBITDA Margin: 23.20%
Is Revvity, Inc.’s EBITDA margin high or low?
Revvity, Inc.'s EBITDA margin of 23.20% is 27% below its 5-year average of 31.56%, near the low end of its 5-year range (23.20%–42.25%).
As of Wednesday, June 17, 2026. 13.59% below its 12-month average of 26.85%.
RVTY EBITDA Margin Chart
RVTY Average EBITDA Margin Chart
RVTY Current vs Average EBITDA Margin Chart
RVTY EBITDA Margin Metrics
EBITDA MARGIN
23.20%
EBITDA MARGIN AVG TTM
26.85%
EBITDA MARGIN AVG 3Y
28.84%
EBITDA MARGIN AVG 5Y
31.56%
EBITDA MARGIN AVG 10Y
25.47%
EBITDA MARGIN AVG 15Y
21.66%
EBITDA MARGIN AVG 20Y
18.50%
CURRENT VS TTM AVG
-13.59%
CURRENT VS 3Y AVG
-19.55%
CURRENT VS 5Y AVG
-26.50%
CURRENT VS 10Y AVG
-8.90%
CURRENT VS 15Y AVG
+7.13%
CURRENT VS 20Y AVG
+25.40%
RVTY Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Revvity, Inc. (RVTY) | $10.91B | 23.20% | 26.85% | 28.84% | 31.56% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -7.64% | -4.75% | -0.21% | 1.54% |
| Baxter International Inc. (BAX)vs › | $10.19B | 6.81% | 8.65% | 4.13% | 9.00% |
| The Cooper Companies, Inc. (COO)vs › | $12.69B | 25.74% | 26.63% | 26.11% | 26.16% |
| Align Technology, Inc. (ALGN)vs › | $12.86B | 18.98% | 19.70% | 20.24% | 21.46% |
| Solventum Corporation (SOLV)vs › | $12.91B | 30.62% | 24.56% | 26.05% | 27.07% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.90B | 10.23% | 12.29% | 18.59% | 20.64% |
| Medpace Holdings, Inc. (MEDP)vs › | $13.05B | 22.55% | 23.25% | 21.70% | 21.08% |
| Tempus AI, Inc. (TEM)vs › | $8.51B | -17.48% | -52.76% | -51.11% | -63.28% |
| DaVita Inc. (DVA)vs › | $13.46B | 19.37% | 20.32% | 19.37% | 19.72% |
Margin Comparison
Gross Margin
51.4%
EBITDA Margin
23.2%
Operating Margin
12.4%
Net Margin
8.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
Revvity, Inc. EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Revvity, Inc. EBITDA Margin FAQ
- What is the EBITDA margin for Revvity, Inc. (RVTY)?
- The EBITDA margin for RVTY stock is 23.20%.
- Is Revvity, Inc.'s EBITDA margin high or low?
- Revvity, Inc.'s EBITDA margin of 23.20% is 27% below its 5-year average of 31.56%, near the low end of its 5-year range (23.20%–42.25%).
- What is the TTM average EBITDA margin for Revvity, Inc. (RVTY)?
- The TTM average EBITDA margin for RVTY stock is 26.85%.
- What is the 3Y average EBITDA margin for Revvity, Inc. (RVTY)?
- The 3Y average EBITDA margin for RVTY stock is 28.84%.
- What is the 5Y average EBITDA margin for Revvity, Inc. (RVTY)?
- The 5Y average EBITDA margin for RVTY stock is 31.56%.
- What is the 10Y average EBITDA margin for Revvity, Inc. (RVTY)?
- The 10Y average EBITDA margin for RVTY stock is 25.47%.
- What is the 15Y average EBITDA margin for Revvity, Inc. (RVTY)?
- The 15Y average EBITDA margin for RVTY stock is 21.66%.
- What is the 20Y average EBITDA margin for Revvity, Inc. (RVTY)?
- The 20Y average EBITDA margin for RVTY stock is 18.50%.
Revvity, Inc. EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-28 | 23.20% |
| 2024-12-29 | 30.50% |
| 2023-12-31 | 25.94% |
| 2022-12-31 | 35.71% |
| 2021-12-31 | 42.25% |
| 2020-12-31 | 31.79% |
| 2019-12-31 | 17.85% |
| 2018-12-31 | 18.19% |
| 2017-12-31 | 19.75% |
| 2016-12-31 | 18.23% |
| 2015-12-31 | 16.73% |
| 2014-12-31 | 14.42% |
| 2013-12-31 | 15.31% |
| 2012-12-31 | 10.55% |
| 2011-12-31 | 10.41% |
| 2010-12-31 | 15.67% |
| 2009-12-31 | 12.96% |
| 2008-12-31 | 13.40% |
| 2007-12-31 | 13.69% |
| 2006-12-31 | 14.81% |
| 2005-12-31 | 10.92% |
| 2004-12-31 | 14.22% |
| 2003-12-31 | 14.56% |
| 2002-12-31 | 10.37% |
| 2001-12-31 | 15.05% |
| 2000-12-31 | 18.36% |
| 1999-12-31 | 13.02% |
| 1998-12-31 | 5.83% |
| 1997-12-31 | 11.38% |
| 1996-12-31 | 9.52% |
Related Metrics
About Revvity, Inc.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Prahlad R. Singh